Clinical Research Directory
Browse clinical research sites, groups, and studies.
Journavx to Treat Pain After Thumb Basal Joint Arthroplasty
Sponsor: Rothman Institute Orthopaedics
Summary
The purpose of this study is to find out how well suzetrigine, a newly FDA-approved non-opioid pain medication, works to relieve pain after thumb basal joint replacement surgery. The researchers believe that suzetrigine may provide effective pain relief during recovery without the use of opioid medications.
Official title: A Single-Arm Open-Label Trial Evaluating the Efficacy of Suzetrigine (Journavx) in Multimodal Postoperative Pain Management Following Thumb Basal Joint Arthroplasty
Key Details
Gender
All
Age Range
40 Years - 80 Years
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2026-07-21
Completion Date
2028-12-31
Last Updated
2026-07-23
Healthy Volunteers
Yes
Conditions
Interventions
suzetrigine 100mg
Participants will receive the recommended dosing for suzetrigine, which consists of a 100 mg oral loading dose taken in the recovery room prior to discharge, followed by 50 mg doses taken orally every 12 hours for 5 days, totaling 11 doses.
Acetaminophen
As part of the multimodal pain regimen, participants will also receive acetaminophen (Tylenol) (500 mg, every 4 hours, or 1000 mg, every 8 hours)
Locations (1)
Rothman Orthopaedic Institute
Philadelphia, Pennsylvania, United States